おかえりなさい
Click “ログイン” to agree to Cointime’s 利用規約 and acknowledge that Cointime’s プライバシーポリシー applies to you.
アカウント登録
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">利用規約</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">プライバシーポリシー</a> applies to you.
siteでログインする
siteで登録する
あなたのメールアドレス
受信トレイを確認する
Click the link we sent to to sign in.
Click the link we sent to to sign up.
advanceCOR
company
About
advanceCOR is a clinical drug developing company that focuses on therapeutics and diagnostics for heart and vascular diseases.
- 1 - 10
Highlights
Details
- Last Funding Type
- Series Unknown
- Last Funding Money Raised
- €6M
- Industries
- Biotechnology
- Founded date
- Jan 1, 2012
- Number Of Employee
- 1 - 10
- Operating Status
- Active
advanceCOR is a clinical drug developing company that focuses on therapeutics and diagnostics for heart and vascular diseases. Its products include Revacept, a human Fc fusion protein, which prevents the local activation of platelets at sites of vascular injury; COR-2, a recombinant protein that interferes with the generation of foam cells; and COR-3, a recombinant protein, which specifically binds to atherosclerotic plaques, and then bi-specifically binds to circulating progenitor cells to trap the endogenously occurring progenitor cells for accelerated plaque healing.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
€6M
advanceCOR has raised a total of
€6M
in funding over 2 rounds. Their latest funding was raised on
May 21, 2018 from a Series Unknown round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| May 21, 2018 | Series Unknown | €6M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
advanceCOR is funded by 1 investors.
Bayern Kapital
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Bayern Kapital
|
— | Series Unknown |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
